Illumina secures CMS reimbursement for TruSight Oncology Comprehensive, expanding access to precision oncology
Illumina to Announce Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 5, 2026
Illumina whole-genome sequencing provides greater insight into genetic signals behind common diseases--according to Nature study
Illumina® Protein Prep delivers groundbreaking precision in NGS proteomics for more than 40 customers, ranging from academic institutions to large national biobanks
Illumina fuels multiomic discovery with launch of 5-base solution, unlocking simultaneous genomic and epigenomic insights
Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine
Jura Announces Dismissal in Full of PEL's Appeal against certain reliefs granted in the Settlement Agreement Arbitral Award
